MRG 004A
Alternative Names: MRG-004; MRG004ALatest Information Update: 14 Jun 2024
At a glance
- Originator Miracogen
- Developer Lepu Biopharma
- Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 12 Jun 2024 Efficacy and adverse event data from phase I/II trial in Solid tumours presented at the American Society of Clinical Oncology (ASCO-2024)
- 28 Mar 2024 No recent reports of development identified for phase-I development in Solid-tumours in China (IV)
- 11 Mar 2024 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV) (NCT04843709)